U.S. FDA Authorizes IND Application for Aastrom's First Cardiac Regeneration Clinical Trial
Ann Arbor, Michigan, U.S.A 23 June 2008  Aastrom to Initiate Phase II Clinical Trial Using Cardiac Repair Cells Derived From Patient's Own Bone Marrow for Treatment of Severe Chronic Heart Failure
---------------------------------------------------------------------------------------------------------
Stem Cell Activation Discovery Holds Promise For Lung Tissue Repair
Philadelphia, Pennsylvania, U.S.A 23 June 2008  Activation of a molecular pathway important in stem cell and developmental biology leads to an increase in lung stem cells, according to researchers from the University of Pennsylvania School of Medicine, and harnessing this knowledge could help develop therapies for lung-tissue repair after injury or disease.
---------------------------------------------------------------------------------------------------------
Boston Researchers Discover New Source Of Heart Stem Cells
Boston, Massachusetts, U.S.A 23 June 2008  Researchers in Massachusetts have pinpointed previously unrecognized stem cells that give rise to cardiomyocytes, or heart muscle cells. The cells, located in the surface of the heart, advance the hope of being able to regenerate injured heart tissue. The work was performed by scientists William Pu, M.D., a pediatric cardiologist at Children’s and the study’s senior investigator, and Bin Zhou, M.D., a research fellow in Pu’s laboratory and the study’s first author, at the Children’s Hospital Boston.
---------------------------------------------------------------------------------------------------------
Adult Stem Cells Aid Fracture Healing; UNC Study Lays Groundwork For Potential Treatments
San Francisco, California, U.S.A 23 June 2008  In an approach that could become a new treatment for the 10 to 20 percent of people whose broken bones fail to heal, researchers at the University of North Carolina at Chapel Hill have shown that transplantation of adult stem cells can improve healing of fractures.
---------------------------------------------------------------------------------------------------------
ThermoGenesis Announces Filing of Pre-Market Notification Application for MarrowXpress
Rancho Cordova, California, U.S.A. 04 June 2008  ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, today announced that it has submitted a 510(k) pre-market notification application to the FDA requesting regulatory clearance for its MarrowXpress(TM) (MXP(TM)), a device designed for the processing of bone marrow in a laboratory setting. The device is a derivative of the Company's approved AutoXpress(TM) (AXP(TM)) Platform that is used to volume reduce and collect stem cells from umbilical cord blood.
---------------------------------------------------------------------------------------------------------
<< Previous 1 2 3 4 5 6 Next >> |
